Stock Comparison

AMIX vs JNJ

Autonomix Medical Inc vs Johnson & Johnson

The Verdict

AMIX takes this one.

Winner

AMIX

Autonomix Medical Inc

5.3

out of 10

Proceed with Caution

JNJ

Johnson & Johnson

1.0

out of 10

Distressed

Head-to-Head

$4M

Market Cap

$557.1B

N/A

P/E Ratio

26.5

N/A

Profit Margin

21.8%

-228.8%

Return on Equity

26.3%

N/A

Debt-to-Equity

0.6

Aggressive

Overall Risk

Conservative

5.3

DVR Score

1.0

The Deep Dive

AMIX5.3/10

Autonomix Medical Inc. (AMIX) remains an extremely speculative micro-cap with immense 10x growth potential if its proprietary nerve signal analysis platform achieves clinical and regulatory success. The intrinsic market opportunity in nerve-related conditions and the potential competitive advantage are strong. Recent clinical progress, evidenced by abstract acceptance for Digestive Disease Week 20...

Full AMIX Analysis

JNJ1.0/10

Johnson & Johnson (JNJ) continues to demonstrate robust financial performance, with Q1 2026 results exceeding consensus on both revenue and adjusted EPS, reflecting nearly 10% YoY revenue growth. Its diversified healthcare portfolio provides significant market leadership and a wide economic moat, indicating stability and consistent profitability. However, its massive market capitalization of $555....

Full JNJ Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.